𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumor: being younger and getting less benefit from adjuvant tamoxifen treatment

✍ Scribed by K. Yu; G. Di; J. Wu; J. Lu; K. Shen; Z. Shen; Z. Shao

Book ID
119598251
Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
58 KB
Volume
6
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Benefit and projected cost-effectiveness
Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor–positive breast cancer
✍ Bruce E. Hillner πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 125 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Women who have estrogen receptor (ER)‐positive disease with postmenopausal onset and who receive tamoxifen as standard adjuvant treatment constitute the largest subgroup of patients with breast cancer. Recent data from the ATAC (β€˜Arimidex, Tamoxifen Alone or in Combinatio

Five versus more than five years of tamo
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors: Fisher B, Dignam J, Bryant J, DeCillis A, Wickeham L, Wolmark N, Constantino J, Redmond C, Fisher ER, Bowman DM, DeschΓͺnes L, Dimitrov NV, Margolese RG, Robidoux R, Shibata H, Terz A, Paterson AHG, Feldman MI, Farrar W, Evans J, Lickney HL J Natl Cancer Inst 1996:88:1529-42
πŸ“‚ Article πŸ“… 1997 πŸ› Elsevier Science 🌐 French βš– 115 KB